Overview

Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis

Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
This pilot study is being done to see if the study medication, Rituximab, preserves kidney function after 12 months of taking the drug.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Genentech, Inc.
Treatments:
Rituximab